Monitor the Biomedical Evidence that Matters to You with Custom-Tailored Intelligence

Request a Demo
Posts Currently viewing the category: "Biomarkers"

This is the first of a 5 installment series covering what we’ve learned about effective biomarker knowledge management over the last few years. The topic will be driven by a “maturity model” that we’ve developed while working with our pharmaceutical, diagnostic and consulting clients. The model outlines the common practice of our clients…(Read More)

In BiomarkerBase we track biomarker use in trials, including those biomarkers used as patient selection criteria in particular clinical trials. We used this capability in a report we recently co-authored with BIO and Informa on clinical trials success rates (spoiler: patient selection biomarkers increase likelihood of approval significantly). For this chart of the week…(Read More)

It is more costly to get biomarker information from public sources than you think. The volume of information requires technology assistance to be efficient. AI approaches like Natural Language Processing (NLP) are the best bet for efficient gathering of clinical information…(Read More)

The team at Amplion, inventors of BiomarkerBase, is proud to share a podcast we did with The Bio Report, a member of the Levine Media Group. The Bio Report specializes in taking complex ideas at the intersection of biotechnology, business, policy, and science and making them accessible in an easy-to-digest podcast format. Take…(Read More)

An interesting article was published today in the Journal of Precision Medicine describing the importance of testing psychiatry patients for mutations in two companion diagnostic biomarkers, CYP2D6 and CYP2C19. These are indeed important biomarkers for safe administration of antidepressants and other psychiatric drugs, which over 10% of the American population receive.  They also happen to…(Read More)

For the chart of the week we wanted to explore the market for multi-analyte panels.  We found that single biomarker tests still vastly outnumber panels.  Stay tuned for more trending information in the coming weeks.  My hypothesis: Panels, even outside of NGS, are being introduced to the market faster than single biomarker tests. Share…(Read More)

Biomarkers triple clinical trial success rate, says report By Melissa Fassbender, 26-May-2016 A recent study of clinical drug development success rates found that biomarker-enabled drug programs are three times more likely to reach approval. http://www.outsourcing-pharma.com/Preclinical-Research/Biomarkers-triple-clinical-trial-success-rate-says-report Download the full…(Read More)

New Report from Amplion, BIO, and BioMedTracker examined ~10,000 clinical trials to make groundbreaking conclusion regarding biomarkers. Bend, Ore., May 25, 2016., May 25, 2016 – Amplion (developers of BiomarkerBaseTM), Biomedtracker, and BIO announces the publication of the largest study of clinical drug development success rates ever. The report examines ~10,000 clinical programs by…(Read More)

New Report from Amplion, BIO, and BioMedTracker examined ~10,000 clinical trials to make groundbreaking conclusion regarding biomarkers. 09:25 ET from Amplion BEND, Ore., May 25, 2016 /PRNewswire/ — Amplion (inventors of BiomarkerBase™), Biomedtracker, and BIO announces the publication of the largest study of clinical drug development success rates ever. The report examines ~10,000…(Read More)

PageLines